+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Retinal Biologics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

  • Report

  • 100 Pages
  • February 2022
  • Region: Global
  • Infinium Global Research
  • ID: 5557572
The report on the global retinal biologics market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global retinal biologics market to grow with a CAGR of 11.21% over the forecast period from 2021-2027. The study on retinal biologics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, RoW, North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.



The report on retinal biologics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global retinal biologics market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global retinal biologics market over the period of 2019 to 2027. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings


1) Drivers

  • The growing geriatric population and associated diseases such as age-related macular degeneration (AMD).
  • Heavy investment in R&D activities related to retinal biologics.
  • Many strategic partnerships between retinal biologics market players.

2) Restraints

  • Insufficient availability of retinal biologics & harmful side effects of biologics.

3) Opportunities

  • Rising geriatric population.

Research Methodology


A) Primary Research


Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research


Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global retinal biologics market is segmented on the basis of drug class, indication, and distribution channel.

The Global Retinal Biologics Market by Drug Class

  • TNF-Alpha Inhibitor
  • VEGF-A Antagonist

The Global Retinal Biologics Market by Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis

The Global Retinal Biologics Market by Distribution Channel

  • Hospitals
  • Clinics
  • Pharmacies

Company Profiles


The companies covered in the report include
  • Regeneron Pharmaceuticals Inc. (US)
  • Ocular Therapeutixc.(US)
  • Spark Therapeutics (US)
  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • AbbVie Inc. (US)
  • Johnson & Johnson Services, Inc. (US)
  • Amgen Inc. (US)
  • MeiraGTx Limited (US)

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the retinal biologics market.
2. Complete coverage of all the segments in the retinal biologics market to analyze the trends, developments in the global market and forecast of market size up to 2027.
3. Comprehensive analysis of the companies operating in the global retinal biologics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Frequently Asked Questions about the Global Retinal Biologics Market

What is the estimated value of the Global Retinal Biologics Market?

The Global Retinal Biologics Market was estimated to be valued at $18.15 Billion in 2021.

What is the growth rate of the Global Retinal Biologics Market?

The growth rate of the Global Retinal Biologics Market is 11.2%, with an estimated value of $34.34 Billion by 2027.

What is the forecasted size of the Global Retinal Biologics Market?

The Global Retinal Biologics Market is estimated to be worth $34.34 Billion by 2027.

Who are the key companies in the Global Retinal Biologics Market?

Key companies in the Global Retinal Biologics Market include Regeneron Pharmaceuticals Inc. (US), Ocular Therapeutixc.(US), Spark Therapeutics (US), Hoffmann, La Roche Ltd (Basel, Switzerland), AbbVie Inc. (US), Johnson & Johnson Services, Inc. (US), Amgen Inc. (US) and MeiraGTx Limited (US).

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Retinal Biologics Market Highlights
2.2. Retinal Biologics Market Projection
2.3. Retinal Biologics Market Regional Highlights
3. Global Retinal Biologics Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Retinal Biologics Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Drug Class
3.5.2. Growth Matrix Analysis by Indication
3.5.3. Growth Matrix Analysis by Distribution Channel
3.5.4. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Retinal Biologics Market
4. Retinal Biologics Market Macro Indicator Analysis
5. Global Retinal Biologics Market by Drug Class
5.1. TNF-alpha Inhibitor
5.2. VEGF-A Antagonist
6. Global Retinal Biologics Market by Indication
6.1. Macular Degeneration
6.2. Diabetic Retinopathy
6.3. Uveitis
7. Global Retinal Biologics Market by Distribution Channel
7.1. Hospitals
7.2. Clinics
7.3. Pharmacies
8. Global Retinal Biologics Market by Region 2021-2027
8.1. North America
8.1.1. North America Retinal Biologics Market by Drug Class
8.1.2. North America Retinal Biologics Market by Indication
8.1.3. North America Retinal Biologics Market by Distribution Channel
8.1.4. North America Retinal Biologics Market by Country
8.2. Europe
8.2.1. Europe Retinal Biologics Market by Drug Class
8.2.2. Europe Retinal Biologics Market by Indication
8.2.3. Europe Retinal Biologics Market by Distribution Channel
8.2.4. Europe Retinal Biologics Market by Country
8.3. Asia-Pacific
8.3.1. Asia-Pacific Retinal Biologics Market by Drug Class
8.3.2. Asia-Pacific Retinal Biologics Market by Indication
8.3.3. Asia-Pacific Retinal Biologics Market by Distribution Channel
8.3.4. Asia-Pacific Retinal Biologics Market by Country
8.4. RoW
8.4.1. RoW Retinal Biologics Market by Drug Class
8.4.2. RoW Retinal Biologics Market by Indication
8.4.3. RoW Retinal Biologics Market by Distribution Channel
8.4.4. RoW Retinal Biologics Market by Sub-region
9. Company Profiles and Competitive Landscape
9.1. Competitive Landscape in the Global Retinal Biologics Market
9.2. Companies Profiled
9.2.1. Regeneron Pharmaceuticals Inc. (US)
9.2.2. Ocular Therapeutixc.(US)
9.2.3. Spark Therapeutics (US)
9.2.4. Hoffmann-La Roche Ltd (Basel, Switzerland)
9.2.5. AbbVie Inc. (US)
9.2.6. Johnson & Johnson Services, Inc. (US)
9.2.7. Amgen Inc. (US)
9.2.8. MeiraGTx Limited (US)

Companies Mentioned

  • Regeneron Pharmaceuticals Inc. (US)
  • Ocular Therapeutixc.(US)
  • Spark Therapeutics (US)
  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • AbbVie Inc. (US)
  • Johnson & Johnson Services, Inc. (US)
  • Amgen Inc. (US)
  • MeiraGTx Limited (US)